Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Phase 1

Completed

Conditions: Cancer
Non-Small Cell Lung Cancer
Endometrial Carcinoma
Ovarian Carcinoma

Interventions: Drug: XL147 (SAR245408),
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2008-09-22

Last Posted Date: 2013-04-10

Lead Sponsor: Sanofi

Target Recruit Count: 52

Registration Number: NCT00756847

Locations: 🇺🇸
Investigational Site Number, Madison, Wisconsin, United States

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Phase 3

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin
Drug: Rimonabant
Drug: placebo

First Posted Date: 2008-09-18

Last Posted Date: 2016-05-17

Lead Sponsor: Sanofi

Registration Number: NCT00754689

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Teriflunomide

First Posted Date: 2008-09-12

Last Posted Date: 2016-07-07

Lead Sponsor: Sanofi

Target Recruit Count: 1169

Registration Number: NCT00751881

Locations: 🇺🇸
Sanofi-Aventis Investigational Site Number 840020, Charleston, West Virginia, United States
🇺🇸
Sanofi-Aventis Investigational Site Number 840060, Syracuse, New York, United States
🇺🇸
Sanofi-Aventis Investigational Site Number 840078, Dayton, Ohio, United States

and more 190 locations

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Sitagliptin
Drug: Metformin

First Posted Date: 2008-09-11

Last Posted Date: 2012-09-10

Lead Sponsor: Sanofi

Target Recruit Count: 515

Registration Number: NCT00751114

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Phase 3

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: placebo
Drug: AVE5530
Drug: atorvastatin

First Posted Date: 2008-08-26

Last Posted Date: 2016-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 1736

Registration Number: NCT00741715

Locations: 🇵🇷
Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico

Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

Phase 4

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: Fexofenadine

First Posted Date: 2008-08-26

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 264

Registration Number: NCT00741897

Locations: 🇵🇭
Sanofi-aventis administrative office, Makati City, Philippines

Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.

Phase 2

Terminated

Conditions: Malaria

Interventions: Drug: SAR97276A

First Posted Date: 2008-08-21

Last Posted Date: 2010-06-16

Lead Sponsor: Sanofi

Target Recruit Count: 113

Registration Number: NCT00739206

Locations: 🇹🇿
Sanofi-Aventis Administrative Office, Dodoma, Tanzania

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Phase 2

Completed

Conditions: Dengue
Dengue Virus
Dengue Fever
Dengue Hemorrhagic Fever

Interventions: Biological: Chimeric dengue serotype (1, 2, 3, 4)

First Posted Date: 2008-08-08

Last Posted Date: 2018-02-27

Lead Sponsor: Sanofi

Target Recruit Count: 35

Registration Number: NCT00730288

Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.

Phase 3

Completed

Conditions: Hygiene

Interventions: Drug: Cetylpyridinium chloride

First Posted Date: 2008-08-07

Last Posted Date: 2009-03-04

Lead Sponsor: Sanofi

Target Recruit Count: 31

Registration Number: NCT00729599

Locations: 🇧🇷
Sanofi-aventis, São Paulo, Brazil

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Phase 3

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: 25 mg/day AVE5530
Drug: 50 mg/day AVE5530
Drug: placebo

First Posted Date: 2008-08-06

Last Posted Date: 2016-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 1015

Registration Number: NCT00729027

Locations: 🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden

Home Terms & Conditions Privacy Policy